147 related articles for article (PubMed ID: 21340661)
1. Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers.
Friedrich C; Ring A; Brand T; Sennewald R; Graefe-Mody EU; Woerle HJ
Eur J Drug Metab Pharmacokinet; 2011 Mar; 36(1):17-24. PubMed ID: 21340661
[TBL] [Abstract][Full Text] [Related]
2. Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.
Friedrich C; Port A; Ring A; Graefe-Mody U; Giessmann T; Iovino M; Woerle HJ
Clin Drug Investig; 2011; 31(9):643-53. PubMed ID: 21714581
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
[TBL] [Abstract][Full Text] [Related]
4. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers.
Graefe-Mody EU; Jungnik A; Ring A; Woerle HJ; Dugi KA
Int J Clin Pharmacol Ther; 2010 Oct; 48(10):652-61. PubMed ID: 20875371
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics and pharmacodynamics of linagliptin.
Graefe-Mody U; Retlich S; Friedrich C
Clin Pharmacokinet; 2012 Jul; 51(7):411-27. PubMed ID: 22568694
[TBL] [Abstract][Full Text] [Related]
7. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
Retlich S; Duval V; Ring A; Staab A; Hüttner S; Jungnik A; Jaehde U; Dugi KA; Graefe-Mody U
Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992
[TBL] [Abstract][Full Text] [Related]
9. Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Graefe-Mody EU; Brand T; Ring A; Withopf B; Stangier J; Iovino M; Woerle HJ
Int J Clin Pharmacol Ther; 2011 May; 49(5):300-10. PubMed ID: 21543033
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects.
Graefe-Mody U; Rose P; Ring A; Zander K; Iovino M; Woerle HJ
Drug Metab Pharmacokinet; 2011; 26(2):123-9. PubMed ID: 21084763
[TBL] [Abstract][Full Text] [Related]
11. Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin.
Graefe-Mody U; Huettner S; Stähle H; Ring A; Dugi KA
Int J Clin Pharmacol Ther; 2010 Jun; 48(6):367-74. PubMed ID: 20497745
[TBL] [Abstract][Full Text] [Related]
12. Bioequivalence of Linagliptin 5 mg once daily and 2.5 mg twice daily: pharmacokinetics and pharmacodynamics in an open-label crossover trial.
Friedrich C; Jungnik A; Retlich S; Ring A; Meinicke T
Drug Res (Stuttg); 2014 May; 64(5):269-75. PubMed ID: 24154935
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of linagliptin in subjects with hepatic impairment.
Graefe-Mody U; Rose P; Retlich S; Ring A; Waldhauser L; Cinca R; Woerle HJ
Br J Clin Pharmacol; 2012 Jul; 74(1):75-85. PubMed ID: 22242621
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers.
Friedrich C; Shi X; Zeng P; Ring A; Woerle HJ; Patel S
Int J Clin Pharmacol Ther; 2012 Dec; 50(12):889-95. PubMed ID: 23073142
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
Heise T; Graefe-Mody EU; Hüttner S; Ring A; Trommeshauser D; Dugi KA
Diabetes Obes Metab; 2009 Aug; 11(8):786-94. PubMed ID: 19476474
[TBL] [Abstract][Full Text] [Related]
16. Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin.
Kadokura T; Groenendaal D; Heeringa M; Mol R; Verheggen F; Garcia-Hernandez A; Onkels H
Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):1-9. PubMed ID: 23754514
[TBL] [Abstract][Full Text] [Related]
17. A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers.
Kang WY; Lee HW; Gwon MR; Cho S; Shim WS; Lee KT; Yang DH; Seong SJ; Yoon YR
Drug Des Devel Ther; 2020; 14():2101-2111. PubMed ID: 32546973
[TBL] [Abstract][Full Text] [Related]
18. Effect of lacosamide on the steady-state pharmacokinetics of digoxin: results from a phase I, multiple-dose, double-blind, randomised, placebo-controlled, crossover trial.
Cawello W; Mueller-Voessing C; Andreas JO
Clin Drug Investig; 2014 May; 34(5):327-34. PubMed ID: 24634110
[TBL] [Abstract][Full Text] [Related]
19. Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods.
Ishiguro N; Shimizu H; Kishimoto W; Ebner T; Schaefer O
Drug Metab Dispos; 2013 Jan; 41(1):149-58. PubMed ID: 23073734
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Scheen AJ
Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
